Roche joins WFH Humanitarian Aid Program

Roche has joined the World Federation of Hemophilia Humanitarian Aid Program, a programme which seeks to improve access to care and treatment for people with inherited bleeding disorders in developing countries. Roche will donate Hemlibra® (emicizumab), a prophylactic treatment for haemophilia A, and provide funding to deliver the WFH Program’s care development training to ensure that local infrastructure and medical expertise are present so the donated Hemlibra can be used appropriately. The donation will provide prophylactic treatment to around 1,000 people with haemophilia A in developing countries over the course of five years.

Alain Weill, WFH President, said: “Thanks to Roche’s donation, significantly more people with haemophilia A will be able to receive prophylaxis through the WFH Humanitarian Aid Program. Importantly, the donation will also provide a treatment option for people with haemophilia A with factor VIII inhibitors who previously had very limited or no treatment. Increasing access to prophylactic treatments can make a profound difference in countries where haemophilia A remains underdiagnosed and untreated.”

Bill Anderson, Chief Executive Officer at Roche Pharmaceuticals, said: “We are proud to join the WFH Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries. Our partnership with the WFH reflects our commitment to the haemophilia community and to supporting rapid, broad and sustainable access to Hemlibra for all people with haemophilia A around the world who may benefit from this important treatment option.”